呼吸机相关性肺炎对急性呼吸窘迫综合征患者的临床影响:一项回顾性队列研究
本研究回顾性纳入两家ICU 18个月内符合柏林标准的ARDS患者336例(COVID-19 101例,其他病因235例),176例(52.4%)发生首次VAP。VAP导致PaO2/FiO2短暂中度下降但SOFA评分未升高,并伴随第28天无呼吸机天数减少19天、无血管活性药天数减少5天,ICU住院延长13天、总住院延长11.5天。全队列90天死亡率VAP组35.8% vs 无VAP组30.0%(P=0.30),但校正后VAP仍独立预测90天死亡(aHR 3.16,95%CI 2.04-4.89,P<0.0001);亚组分析显示非COVID-19患者中VAP预测死亡(aHR 3.43,P<0.0001),COVID-19患者中无统计学关联(aHR 1.19,P=0.80)。
要点
- ARDS患者中VAP发生率52.4%(176/336),VAP组与无VAP组90天死亡率分别为35.8%和30.0%(P=0.30)。
- 全队列校正后VAP独立预测90天死亡(aHR 3.16,95%CI 2.04-4.89,P<0.0001),SAPS-2评分、慢性肾病及因心脏骤停入院亦为预测因素。
- 非COVID-19 ARDS患者中VAP预测90天死亡(aHR 3.43,95%CI 2.11-5.58,P<0.0001),COVID-19患者中无统计学关联(aHR 1.19,95%CI 0.32-4.49,P=0.80)。
- VAP与第28天无呼吸机天数减少19天(中位差值-19,95%CI -20至-13.5)、无血管活性药天数减少5天(95%CI -9至-2)相关。
- VAP与ICU住院延长13天(95%CI +9至+15)、总住院延长11.5天(95%CI +7.5至+17.5)相关,两个亚组均观察到该效应。
适用人群与场景
- 两家大学附属医院ICU在18个月期间收治、符合柏林标准定义的ARDS患者,共336例(COVID-19 101例,其他病因ARDS 235例)。
诊断标准与关键阈值
- ARDS诊断采用柏林标准。
研究设计与关键结果
- 回顾性队列研究,纳入两家ICU的336例ARDS患者,176例(52.4%)发生首次VAP;主要终点为90天死亡概率,采用Cox比例风险模型将VAP作为延迟进入变量处理。
- VAP导致PaO2/FiO2比值短暂中度下降,SOFA评分未升高(线性混合模型)。
- VAP组 vs 无VAP组:第28天无呼吸机天数中位差值-19天(95%CI -20至-13.5),无血管活性药天数差值-5天(95%CI -9至-2),ICU住院差值+13天(95%CI +9至+15),总住院差值+11.5天(95%CI +7.5至+17.5);上述效应在两个亚组中均观察到。
- 90天总死亡率VAP组35.8% vs 无VAP组30.0%(P=0.30)。
- 全队列校正后,VAP预测90天死亡(aHR 3.16,95%CI 2.04-4.89,P<0.0001);入院时SAPS-2值、慢性肾病及因心脏骤停入院亦为预测因素;COVID-19状态无独立影响。
- 亚组分析:非COVID-19患者中VAP预测死亡(aHR 3.43,95%CI 2.11-5.58,P<0.0001);COVID-19患者中VAP无统计学关联(aHR 1.19,95%CI 0.32-4.49,P=0.80)。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在ARDS患者中,VAP与90天死亡风险独立相关(aHR 3.16),且与无呼吸机天数、无血管活性药天数减少及住院时间延长相关;该关联在非COVID-19 ARDS患者中显著(aHR 3.43),在COVID-19相关ARDS患者中未达统计学显著(aHR 1.19,95%CI 0.32-4.49,P=0.80)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The clinical impact and outcomes of ventilator-associated pneumonia (VAP) have been scarcely investigated in patients with the acute respiratory distress syndrome (ARDS).
METHODS: Patients admitted over an 18-month period in two intensive care units (ICU) of a university-affiliated hospital and meeting the Berlin criteria for ARDS were retrospectively included. The association between VAP and the probability of death at day 90 (primary endpoint) was appraised through a Cox proportional hazards model handling VAP as a delay entry variable. Secondary endpoints included (i) potential changes in the PaO2/FiO2 ratio and SOFA score values around VAP (linear mixed modelling), and (ii) mechanical ventilation (MV) duration, numbers of ventilator- and vasopressor-free days at day 28, and length of stay (LOS) in patients with and without VAP (median or absolute risk difference calculation). Subgroup analyses were performed in patients with COVID-19-related ARDS and those with ARDS from other causes.
RESULTS: Among the 336 included patients (101 with COVID-19 and 235 with other ARDS), 176 (52.4%) experienced a first VAP. VAP induced a transient and moderate decline in the PaO2/FiO2 ratio without increase in SOFA score values. VAP was associated with less ventilator-free days (median difference and 95% CI, - 19 [- 20; - 13.5] days) and vasopressor-free days (- 5 [- 9; - 2] days) at day 28, and longer ICU (+ 13 [+ 9; + 15] days) and hospital (+ 11.5 [+ 7.5; + 17.5] days) LOS. These effects were observed in both subgroups. Overall day-90 mortality rates were 35.8% and 30.0% in patients with and without VAP, respectively (P = 0.30). In the whole cohort, VAP (adjusted HR 3.16, 95% CI 2.04-4.89, P < 0.0001), the SAPS-2 value at admission, chronic renal disease and an admission for cardiac arrest predicted death at day 90, while the COVID-19 status had no independent impact. When analysed separately, VAP predicted death in non-COVID-19 patients (aHR 3.43, 95% CI 2.11-5.58, P < 0.0001) but not in those with COVID-19 (aHR 1.19, 95% CI 0.32-4.49, P = 0.80).
CONCLUSIONS: VAP is an independent predictor of 90-day mortality in ARDS patients. This condition exerts a limited impact on oxygenation but correlates with extended MV duration, vasoactive support, and LOS.
参考来源
- Le Pape M, Besnard C, Acatrinei C, et al. Clinical impact of ventilator-associated pneumonia in patients with the acute respiratory distress syndrome: a retrospective cohort study. Ann Intensive Care. 2022. PMID: 35290537. doi:10.1186/s13613-022-00998-7
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。